the bioscience ecosystem of the future · 2 modeled after: jack w. scannell, alex blanckley, helen...
TRANSCRIPT
The Bioscience Ecosystem of the Future
John C. Lechleiter, Ph.D.
Chairman, President, and Chief Executive Officer
CED Life Science Conference
March 3, 2015
2
Modeled after: Jack W. Scannell, Alex Blanckley, Helen Boldon & Brian Warrington,
“Diagnosing the decline in pharmaceutical R&D efficiency,” Nature Reviews Drug Discovery 11, 191-200 (March 2012)
Number of Drugs per Billion US$ R&D Spending
25+ 9
Lilly
Bristol-Myers SquibbBristol-Myers
Squibb
Sanofi-Aventis
Merck
Glaxo-Smith Kline
Pfizer
Astra-Zeneca
Novartis
Roche
Bristol-Myers Squibb
135
Lilly
Bristol-Myers SquibbBristol-Myers
Squibb
Sanofi-Aventis
Merck
Glaxo-Smith Kline
Pfizer
Astra-Zeneca
Novartis
Roche
Bristol-Myers Squibb
135138
DATES DEALS WERE ANNOUNCED
Genentech (Roc he has held a ma jority stake sinc e 1990 and fully ac quired in 2009.)
The New York Times. Sources: Credit Suisse; company reports; Bloomberg 3
4
Source: Moody’s Analytics, Regional Financial Review, July 2011
Tuition Vs. Other Price Indices
10
15
20
25
30
35
40
45
Success R
ate
(%)
Year Source: National Institutes of Health
5
401.6 397.0 388.9 375.0
355.9
332.0 313.8 309.9
296.3 280.4
266.5 247.8
232.3 211.1
190.9 180.1 173.7
100.0
150.0
200.0
250.0
300.0
350.0
400.0
450.0
1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011
U.S. Death Rates Due to Diseases of the Heart
6
Ag
e-a
dju
ste
d D
ea
th R
ate
s
pe
r 1
00
,000
Sources: U.S. Centers for Disease Control; PhRMA
7
$1,000
$10,000
$100,000
$1,000,000
$10,000,000
$100,000,000
Jan-01 Jan-02 Jan-03 Jan-04 Jan-05 Jan-06 Jan-07 Jan-08 Jan-09 Jan-10 Jan-11 Jan-12 Jan-13 Jan-14
Cost per Genome
The cost per genome has declined from $95,263,072 in Sept. 2001 to $5,096 in Oct. 2013
Source: NIH, National Human Genome Research Institute
Logarithmic Scale
Project-focused companies (PFCs)
>
•
•
•
© 2015 Eli Lilly and Company 8
New vehicles to access and advance
clinical-stage molecules
© 2015 Eli Lilly and Company 9
Model/Company Therapeutic Area Investors Origin of Asset
PFC: Tensha Oncology HealthCare Ventures Academia
PFC: Ixchelsis Men’s Health TVM Pharma
PFC: GLWL Research Diabetes TVM Lilly
PFC: Kaneq Diabetes TVM Pharma
PFC: Apofore Diabetes HealthCare Ventures Academia
PFC: FAAH Pain TVM Biotech
PFC: PRCL Autoimmune TVM Biotech
Non-PFC: Edinburgh Molecular Imaging Oncology Epidarex Academia
Non-PFC: Sirakoss Bone Epidarex Medical Device
Non-PFC: Enterprise Respiratory Epidarex Biotech
PFC: Project Focused Company
Public-private partnerships in
Alzheimer’s Disease research
11
A4
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
• Important role in mapping out the natural history of AD, thus facilitating
biomarker assessment
Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4)
• Prevention clinical trial treating patients with deposited amyloid in the
brain but minimal symptoms
The Dominantly Inherited Alzheimer’s Network (DIAN)
• Washington University School of Medicine conducting worldwide
clinical study of early-onset AD
AD
NI
A4
D
IAN
The Bioscience Ecosystem of the Future